These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
2 files

Evaluation of Potent Isoquinoline-Based Thiosemicarbazone Antiproliferatives Against Solid Tumor Models

submitted on 22.03.2019, 22:40 and posted on 25.03.2019, 16:53 by Daniel Sun, Soumya Poddar, Roy D. Pan, Juno Van Valkenburgh, Ethan Rosser, Evan Abt, Vincent Lok, Joseph Capri, Selena Hernandez, Janet Song, Joanna Li, Laurent Vergnes, Anthony Cabebe, Wesley Armstrong, Sheba Plamthottam, Dalton Steele, Corey Osto, Andreea Stuparu, Thuc Le, Karen Reue, Robert Damoiseaux, Johanes Czernin, Michael Jung, Caius Radu
The lead compound, an ⍺-N-heterocyclic carboxaldehyde thiosemicarbazone HCT-13, was highly potent against a panel of pancreatic, small cell lung carcinoma, and prostate cancer models, with IC90 values in the low-to-mid nanomolar range. We show that the cytotoxicity of HCT-13 is copper-dependent, that it acts as a copper ionophore, induces production of reactive oxygen species (ROS), and promotes mitochondrial dysfunction and S-phase arrest. Lastly, DNA damage response/replication stress response (DDR/RSR) pathways, specifically Ataxia-Telangiectasia Mutated (ATM) and Rad3-related protein kinase (ATR), were identified as actionable adaptive resistance mechanisms following HCT-13 treatment. Taken together, HCT-13 is potent against solid tumor models and warrants in vivo evaluation against aggressive tumor models, either as a single agent or as part of a combination therapy.


PET Imaging-guided Personalized Therapy in Pancreatic Cancer

National Cancer Institute

Find out more...

Trethera Corporation 20162965

NSF Graduate research fellowship program no. DGE-1650504


Email Address of Submitting Author




United States

ORCID For Submitting Author


Declaration of Conflict of Interest

no conflicts of interest